

ImmunoGen

[View the current ImmunoGen Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/5298-ImmunoGen.html)

(<http://www.bioportfolio.com/biocorporate/5298-ImmunoGen.html>)

Contact Details:

128 Sidney Street

Cambridge

MA

02139

United States of America

Tel: (617) 995-2500

Fax: 617-995-2510

Email:

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates are called tumor-activated prodrugs ("TAPs") and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, TAPs are intended to deliver potent chemotherapy specifically to a tumor. Each TAP immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody. The small-molecule drugs are highly potent cell-killing (cytotoxic) agents, while the monoclonal antibodies identify and bind to tumor cells. An important characteristic of TAPs is that they remain inactive and nontoxic until they bind to the surface of a tumor cell, after which their full cytotoxicity is restored.

Recent Publications by ImmunoGen:



- [Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody-Maytansinoid Conjugates.](#)
*Antibody-drug conjugates (ADCs) are designed to eradicate cancer cells...*7th November, 2009
ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451.- *Bioconjug Chem.* 2009 Nov 5. ([DOI Direct Link](#))
- [Antibody-cytotoxic agent conjugates: preparation and characterization.](#)
*Conjugates of antibodies with cytotoxic agents offer a targeted...*23rd April, 2009
ImmunoGen Inc., Waltham, MA, USA.- *Methods Mol Biol.* 2009;525:445-67, xiv. ([DOI Direct Link](#))
- [Targeted cancer therapy: conferring specificity to cytotoxic drugs.](#)
*The therapeutic activity of most anticancer drugs in clinical use is...*29th May, 2008
ImmunoGen, Inc., 128 Sidney Street, Cambridge, Massachusetts 02139, USA.- *Acc Chem Res.* 2008 Jan;41(1):98-107. Epub 2007 Aug 18. ([DOI Direct Link](#))
- [Cell killing by antibody-drug conjugates.](#)

- Antibody-drug conjugates (ADCs) are designed to specifically bind to and...* 10th November, 2007
ImmunoGen Inc., 128 Sidney Street, Cambridge, MA 02139-4239, USA.- *Cancer Lett.* 2007 Oct 8;255(2):232-40. Epub 2007 Jun 5. ([DOI Direct Link](#))
- [The rabies peripheral challenge test: more accurate determination of vaccine potency.](#)
The National Institutes of Health (NIH) rabies vaccine potency test is... 5th January, 2007
ImmunoGen Inc., 128 Sidney Street, Cambridge, MA 02139-4239, USA.- *Vaccine.* 2006 Nov 30;24(49-50):7115-23. Epub 2006 Jul 21. ([DOI Direct Link](#))
 - [Semisynthetic maytansine analogues for the targeted treatment of cancer.](#)
Maytansine, a highly cytotoxic natural product, failed as an anticancer... 12th September, 2006
ImmunoGen, Inc., 128 Sidney Street, Cambridge, Massachusetts 02139, USA.- *J Med Chem.* 2006 Jul 13;49(14):4392-408. ([DOI Direct Link](#))
 - [Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.](#)
Antibody-drug conjugates are targeted anticancer agents consisting of a... 8th June, 2006
ImmunoGen, Inc., Cambridge, Massachusetts 02139, USA.- *Cancer Res.* 2006 Apr 15;66(8):4426-33. ([DOI Direct Link](#))
 - [In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer.](#)
It is a commonly held belief that most treatments for disseminated cancers... 7th June, 2006
ImmunoGen, Inc.,- *Expert Opin Biol Ther.* 2006 Mar;6(3):281-91. ([DOI Direct Link](#))
 - [Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.](#)
Conjugates of the anti-CanAg humanized monoclonal antibody huC242 with the... 4th May, 2006
ImmunoGen, Inc., Cambridge, Massachusetts 02139, USA.- *Cancer Res.* 2006 Mar 15;66(6):3214-21. ([DOI Direct Link](#))
 - [Drug-conjugated monoclonal antibodies for the treatment of cancer.](#)
Early clinical development in the field of targeted delivery of cytotoxic... 8th March, 2006
ImmunoGen Inc.- *Curr Opin Pharmacol.* 2005 Oct;5(5):543-9. ([DOI Direct Link](#))
 - [Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry.](#)
Immunoconjugates are being explored as novel cancer therapies with the... 24th January, 2006
ImmunoGen, Inc., 128 Sidney Street, Cambridge, MA 02139, USA.- *Protein Sci.* 2005 Sep;14(9):2436-46. Epub 2005 Aug 4. ([DOI Direct Link](#))
 - [Cell death suppression by cytomegaloviruses.](#)
Cytomegaloviruses (CMVs), a subset of betaherpesviruses, employ multiple... 13th December, 2005
ImmunoGen, Inc., 128 Sidney St., Cambridge, MA 02139, USA.- *Apoptosis.* 2005 Mar;10(2):251-65. ([DOI Direct Link](#))
 - [Structural characterization of a recombinant monoclonal antibody by electrospray time-of-flight mass spectrometry.](#)
PURPOSE: The aim of this study was to perform structural characterization... 14th October, 2005
ImmunoGen, Inc., Cambridge, Maryland 02139, USA.- *Pharm Res.* 2005 Aug;22(8):1338-49. Epub 2005 Aug 3. ([DOI Direct Link](#))
 - [Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry.](#)
Recombinant monoclonal antibody drug products play an increasingly... 1st October, 2005
ImmunoGen, Inc., 128 Sidney Street, Cambridge, MA 02139, USA.- *Rapid Commun Mass Spectrom.* 2005;19(13):1806-14. ([DOI Direct Link](#))
 - [Capsid structure and dynamics of a human rhinovirus probed by hydrogen exchange mass spectrometry.](#)
Viral capsids are dynamic protein assemblies surrounding viral genomes... 20th September, 2005
Department of Chemistry, University of Nebraska, Lincoln 68588-0304, USA.- *Protein Sci.* 2005 Jun;14(6):1661-72. Epub 2005 May 9. ([DOI Direct Link](#))

Press Releases on ImmunoGen:

ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PIGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumours	16th November, 2009		<i>LEUVEN, Belgium and LUND, Sweden, November 16 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS: BINV) today announced positive results from a Phase I</i>
Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment	26th October, 2009	Reportlinker	<i>-- A focus on "engineered" antibodies Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing</i>
New Report Just Published: World Multiple Myeloma Therapeutics Market Report	7th July, 2009	Reportlinker	<i>NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue. World Multiple Myeloma Therapeutics Market http://www.reportlinker.com/p0119496/World</i>
MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development	23rd January, 2009	MedPredict	<i>SCOTTSDALE, Ariz., Jan. 23 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published two new reports providing</i>
Bioinvent's Candidate Drug Against Hiv/Aids Approved To Enter Clinical	1st May, 2005	Bioinvent	<i>Bioinvent's Candidate Drug Against Hiv/Aids Approved To Enter Clinical Trials In UK Lund, Sweden: 18 May 2005 - BioInvent (SAX: BINV) has obtained approval from the</i>

BioNews Results for ImmunoGen



- [Sinovac Reports Unaudited Third Quarter 2009 Financial Results](#)
TickerTech.com: Nov 16 2009 2:02AM Matching: immunogen
- [Sinovac Reports Unaudited Third Quarter 2009 Financial Results](#)
KOTA Territory News: Nov 16 2009 12:36AM Matching: immunogen
- [XTEN Data From Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum](#)
Genetic Engineering News: Nov 15 2009 8:47PM Matching: immunogen
- [XTEN Data From Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum](#)
Sys-Con Canada: Nov 15 2009 8:39PM Matching: immunogen

- [XTEN Data From Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum](#)
Sys-Con Media: Nov 15 2009 8:28PM Matching: immunogen
- [XTEN Data From Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum](#)
RBC Dain Rauscher: Nov 15 2009 8:21PM Matching: immunogen
- [XTEN Data From Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum Half-Life](#)
NewsBlaze: Nov 15 2009 7:36PM Matching: immunogen
- [XTEN Data From Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Inceas](#)
Interest!ALERT: Nov 15 2009 6:51PM Matching: immunogen
- [XTEN Data From Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum](#)
Reuters: Nov 15 2009 6:33PM Matching: immunogen
- [XTEN Data From Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum](#)
Genetic Engineering News: Nov 15 2009 6:31PM Matching: immunogen
- [XTEN Data From Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for PR inside](#)
Nov 15 2009 6:29PM Matching: immunogen
- [XTEN Data From Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum](#)
Yahoo! Canada: Nov 15 2009 6:04PM Matching: immunogen
- [XTEN Data From Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum](#)
Market Wire: Nov 15 2009 6:03PM Matching: immunogen
- [XTEN Data From Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum](#)
Marketwire via Yahoo!: Nov 15 2009 6:02PM Matching: immunogen
- [XTEN Data From Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum](#)
Street Insider: Nov 15 2009 6:01PM Matching: immunogen

ImmunoGen Clinical Trials:



- [huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas](#)



ImmunoGen Patents:

- 6441163- [Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents](#)
- 7097840- [Methods of treatment using anti-ErbB antibody-maytansinoid conjugates](#)
- 7097982- [Peptides and compositions which modulate apoptosis](#)
- 7186851- [Facile method for synthesizing baccatin III compounds](#)
- 7192750- [Mutant Actinosynnema pretiosum strain with increased maytansinoid production](#)
- 7193044- [Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis](#)
- 7202024- [bbc3 Gene promoter and methods for identifying modulators of apoptosis and bbc3 gene expression using a bbc3 gene promoter](#)
- 7202346- [Antibodies to non-shed Muc1 and Muc16, and uses thereof](#)
- 7217819- [Cytotoxic agents comprising taxanes and their therapeutic use](#)
- 7276497- [Cytotoxic agents comprising new maytansinoids](#)
- 7276499- [Cytotoxic agents comprising taxanes and their therapeutic use](#)
- 7078175- [Antibodies for apoptosis EI24 protein and methods of use](#)
- 7049316- [Prodrugs of CC-1065 analogs](#)
- 6534660- [CC-1065 analog synthesis](#)
- 6586618- [CC-1065 analog synthesis](#)
- 6596757- [Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use](#)
- 6630579- [Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use](#)
- 6706708- [Cytotoxic agents comprising taxanes and their therapeutic use](#)
- 6716821- [Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same](#)
- 6756397- [Prodrugs of CC-1065 analogs](#)
- 6790954- [Mutant Actinosynnema pretiosum strain with increased maytansinoid production](#)
- 6913748- [Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs](#)
- 7008942- [Cytotoxic agents comprising taxanes and their therapeutic use](#)
- 7301019- [Method for the preparation of maytansinoid esters](#)
- 7303749- [Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents](#)
- 7329760- [CC-1065 analog synthesis](#)
- 7494649- [Drug conjugate composition](#)
- 7495114- [Cytotoxic agents containing novel potent taxanes and their therapeutic use](#)
- 7501120- [Drug conjugate composition](#)
- 7514080- [Drug conjugate composition](#)
- 7528130- [Cytotoxic agents comprising taxanes and their therapeutic use](#)
- 7538195- [Anti-IGF-I receptor antibody](#)
- 7550609- [Cytotoxic agents comprising taxanes and their therapeutic use](#)
- 7557189- [Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same](#)
- 7585857- [Cytotoxic agents comprising taxanes and their therapeutic use](#)
- 7598290- [Cytotoxic agents comprising new C-2 modified taxanes](#)
- 7476669- [Cytotoxic agents comprising taxanes and their therapeutic use](#)
- 7473796- [Cytotoxic agents comprising new maytansinoids](#)

- 7342110- [Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same](#)
- 7358088- [Peptides and compositions which modulate apoptosis](#)
- 7368565- [Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents](#)
- 7374762- [Drug conjugate composition](#)
- 7388026- [Prodrugs of CC-1065 analogs](#)
- 7390898- [Cytotoxic agents containing novel potent taxanes and their therapeutic use](#)
- 7411063- [Process for preparation of maytansinol](#)
- 7414073- [Cytotoxic agents containing novel potent taxanes and their therapeutic use](#)
- 7432088- [Methods for the production of ansamitocins](#)
- 7449450- [Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products](#)
- 7601354- [Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

